Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Daré Bioscience ( (DARE) ) is now available.
On July 24, 2025, Daré Bioscience received confirmation from Nasdaq that it met the stockholders’ equity requirement, ensuring compliance with the Nasdaq Capital Market’s listing rules. However, the company will be under a Mandatory Panel Monitor for one year, and any non-compliance within this period could lead to a delist determination without the opportunity for a compliance plan or additional time to regain compliance.
The most recent analyst rating on (DARE) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Daré Bioscience stock, see the DARE Stock Forecast page.
Spark’s Take on DARE Stock
According to Spark, TipRanks’ AI Analyst, DARE is a Neutral.
Daré Bioscience’s overall stock score is primarily impacted by its challenging financial situation, including negative equity and ongoing losses. However, positive developments in clinical trials and strategic initiatives offer a glimpse of potential future improvement.
To see Spark’s full report on DARE stock, click here.
More about Daré Bioscience
Daré Bioscience operates in the biopharmaceutical industry, focusing on developing innovative products for women’s health, including contraception, fertility, and sexual health.
Average Trading Volume: 1,505,198
Technical Sentiment Signal: Sell
Current Market Cap: $23.28M
See more data about DARE stock on TipRanks’ Stock Analysis page.